Jupiter Bioventures is a venture capital firm uniquely focused on early-stage biotech innovation, targeting scientific ideas that traditional investors often overlook. Founded by Norman Sharpless, former Director of the National Cancer Institute, and Nathaniel David, a serial biotech entrepreneur, the firm is committed to transforming ground-breaking academic discoveries into successful biotech ventures. With an initial $70 million fund, Jupiter deploys up to $2.5 million per project in the early stages to rigorously validate the science, including replicating experiments, initiating medicinal chemistry work, and assessing intellectual property. Only the most promising ideas move forward, with follow-up investments of up to $20 million to help them scale.

Jupiter’s projects, named after moons in the solar system, showcase the firm’s diverse portfolio. Current initiatives include Ganymede, which targets NRF2-dependent cancers, and Deimos, advancing an oral treatment for acute radiation syndrome. Another notable venture, Cavalry Biosciences, explores targeted growth factor delivery to regenerate tissues such as nerves and muscles. With a disciplined approach to funding and a passion for driving transformative science, Jupiter Bioventures is carving out a niche in biotech, supported by prominent partners like Mayo Clinic, Mission BioCapital, and other top-tier investors.